Suppr超能文献

卵巢癌中p53蛋白的免疫染色:与组织病理学数据及临床结果的相关性

Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.

作者信息

Reles A, Schmider A, Press M F, Schönborn I, Friedmann W, Huber-Schumacher S, Strohmeyer T, Lichtenegger W

机构信息

Department of Gynecology and Obstetrics, Virchow-Klinikum, Humboldt-University, Berlin, Germany.

出版信息

J Cancer Res Clin Oncol. 1996;122(8):489-94. doi: 10.1007/BF01187161.

Abstract

OBJECTIVE

The objective of this study was to analyze the incidence of immunohistochemically detectable p53 protein accumulation in epithelial ovarian carcinomas and to correlate these data with the clinical outcome so as to clarify further the role of p53 mutations in prognosis with these patients.

METHODS

Tumor tissues from 179 patients with epithelial ovarian carcinoma were used for immuno-histochemical analysis with monoclonal antibody DO1 and BP 53-12-1 on formalin-fixed, paraffin-embedded tissue.

RESULTS

A total of 78 cases (44%) showed positive nuclear p53 staining. The p53-positive cases were found in all histological types of epithelial ovarian tumors. p53 staining was found in tumors of all stages with a higher percentage of positive cases in stage IV ovarian carcinomas (not significant). Poorly differentiated carcinomas showed a significantly higher percentage of p53 protein expression than did highly differentiated tumors (P = 0.0002). Clinical follow-up of up to 14 years (median 25 months) showed a slightly but not significantly shortened disease-free and overall survival time for patients with p53-positive epithelial ovarian carcinomas.

CONCLUSIONS

We conclude from our data that p53 expression in ovarian carcinoma is associated with poor differentiation but not with the disease being in an advanced stage. There was a tendency for shortened disease-free and overall survival for patients with p53-positive tumors.

摘要

目的

本研究的目的是分析上皮性卵巢癌中免疫组化可检测到的p53蛋白积累的发生率,并将这些数据与临床结果相关联,以进一步阐明p53突变在这些患者预后中的作用。

方法

用单克隆抗体DO1和BP 53-12-1对179例上皮性卵巢癌患者的肿瘤组织进行免疫组化分析,组织为福尔马林固定、石蜡包埋。

结果

共有78例(44%)显示核p53染色阳性。p53阳性病例见于所有组织学类型的上皮性卵巢肿瘤。各期肿瘤均有p53染色,IV期卵巢癌阳性病例百分比更高(无显著性差异)。低分化癌p53蛋白表达百分比显著高于高分化肿瘤(P = 0.0002)。长达14年(中位25个月)的临床随访显示,p53阳性上皮性卵巢癌患者的无病生存期和总生存期略有缩短,但无显著性差异。

结论

我们从数据中得出结论,卵巢癌中p53表达与低分化相关,但与疾病晚期无关。p53阳性肿瘤患者的无病生存期和总生存期有缩短的趋势。

相似文献

4
Optimal primary surgical treatment for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的最佳初次手术治疗
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
5
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.早期上皮性卵巢癌的辅助(术后)化疗。
Cochrane Database Syst Rev. 2012 Mar 14;3(3):CD004706. doi: 10.1002/14651858.CD004706.pub4.
8
Surgical cytoreduction for recurrent epithelial ovarian cancer.复发性上皮性卵巢癌的手术细胞减灭术。
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD008765. doi: 10.1002/14651858.CD008765.pub3.

引用本文的文献

本文引用的文献

1
p53 gene mutations and protein accumulation in human ovarian cancer.人类卵巢癌中的p53基因突变与蛋白积累
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5. doi: 10.1073/pnas.90.11.4961.
4
Clinical implications of the p53 tumor-suppressor gene.p53肿瘤抑制基因的临床意义。
N Engl J Med. 1993 Oct 28;329(18):1318-27. doi: 10.1056/NEJM199310283291807.
6
Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
J Clin Oncol. 1994 Jan;12(1):64-9. doi: 10.1200/JCO.1994.12.1.64.
7
Tumor suppressor genes.肿瘤抑制基因。
Curr Opin Genet Dev. 1994 Feb;4(1):135-41. doi: 10.1016/0959-437x(94)90102-3.
9
p53 expression in ovarian borderline tumors and stage I carcinomas.
Am J Clin Pathol. 1994 Nov;102(5):671-6. doi: 10.1093/ajcp/102.5.671.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验